Two prognostically significant subtypes of high-grade lung neuroendocrine turnours independent of small-cell and large-cell neuroendocrine carcinomas identified by gene expression profiles

被引:179
|
作者
Jones, MH
Virtanen, C
Honjoh, D
Miyoshi, T
Satoh, Y
Okumura, S
Nakagawa, K
Nomura, H
Ishikawa, Y
机构
[1] Univ Tokyo, Proliferat Signal Div, Chugai Pharmaceut Co Ltd, Tokyo, Japan
[2] Invitrogen Japan, Tokyo, Japan
[3] Japanese Fdn Canc Res, Inst Canc, Dept Pathol, Tokyo 170, Japan
[4] Canc Inst Hosp, Dept Chest Surg, Tokyo, Japan
来源
LANCET | 2004年 / 363卷 / 9411期
关键词
D O I
10.1016/S0140-6736(04)15693-6
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Classification of high-grade neuroendocrine tumours (HGNT) of the lung currently recognises large-cell neuroendocrine carcinoma (LCNEC) and small-cell lung carcinoma (SCLC) as distinct groups. However, a similarity in histology for these two carcinomas and uncertain clinical course have led to suggestions that a single HGNT classification would be more appropriate. Gene expression profiling, which can reproduce histopathological classification, and often defines new subclasses with prognostic significance, can be used to resolve HGNT classification. Methods We used cDNA microarrays with 40386 elements to analyse the gene expression profiles of 38 surgically resected samples of lung neuroendocrine tumours and 11 SCLC cell lines. Samples of large-cell carcinoma, adenocarcinoma, and normal lung were also included to give a total of 105 samples analysed. The data were subjected to filtering to yield informative genes before unsupervised hierarchical clustering that identified relatedness of tumour samples. Findings Distinct groups for carcinoids, large-cell carcinoma, adenocarcinoma, and normal lung were readily identified. However, we were unable to distinguish LCNEC from SCLC by gene expression profiling. Three independent rounds of unsupervised hierarchical clustering consistently divided SCLC samples into two main groups with LCNEC samples largely integrated with these groups. Furthermore, patients in one of the groups identified by clustering had a significantly better clinical outcome than the other (83% vs 12% survived for 5 years; p=0.0094. None of the highly proliferative SCLC cell lines subsequently analysed clustered with this good-prognosis group. Interpretation Our findings show that HGNT of the lung can be classified into two groups independent of SCLC and LCNEC. To this end, we have identified many genes, some of which encode well-characterised markers of cancer that distinguish the HGNT groups. These results have implications for the diagnosis, classification, and treatment of lung neuroendocrine tumours, and provide important insights into their underlying biology.
引用
收藏
页码:775 / 781
页数:7
相关论文
共 50 条
  • [31] Differential development of large-cell neuroendocrine or small-cell lung carcinoma upon inactivation of 4 tumor suppressor genes
    Lazaro, Sara
    Perez-Crespo, Miriam
    Lorz, Corina
    Bernardini, Alejandra
    Oteo, Marta
    Belen Enguita, Ana
    Romero, Eduardo
    Hernandez, Pilar
    Tomas, Laura
    Angel Morcillo, Miguel
    Paramio, Jesus M.
    Santos, Mirentxu
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2019, 116 (44) : 22300 - 22306
  • [32] A Case of Small-Cell Neuroendocrine Carcinoma of the Gallbladder in a Background of High-Grade Biliary Intraepithelial Neoplasia
    Alkamachi, B.
    Aldeen, B. Sharaf
    Alhamar, M.
    Jaratli, H.
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2020, 154 : S72 - S72
  • [33] Small-cell neuroendocrine carcinoma of the cervix accompanied by adenocarcinoma and high-grade squamous intraepithelial lesion
    Okabe, Asako
    Ishida, Mitsuaki
    Noda, Yuri
    Okano, Kimiaki
    Sandoh, Kaori
    Fukuda, Hisato
    Kita, Masato
    Okada, Hidetaka
    Tsuta, Koji
    DIAGNOSTIC CYTOPATHOLOGY, 2022, 50 (10) : E285 - E288
  • [34] A pilot study of adjuvant chemotherapy with irinotecan and cisplatin for completely resected high-grade pulmonary neuroendocrine carcinoma (large cell neuroendocrine carcinoma and small cell lung cancer)
    Kenmotsu, Hirotsugu
    Niho, Seiji
    Ito, Takeo
    Ishikawa, Yuichi
    Noguchi, Masayuki
    Tada, Hirohito
    Sekine, Ikuo
    Watanabe, Shun-ichi
    Yoshimura, Masahiro
    Yamamoto, Nobuyuki
    Oshita, Fumihiro
    Kubota, Kaoru
    Nagai, Kanji
    LUNG CANCER, 2014, 84 (03) : 254 - 258
  • [35] The Differences of Biological Behavior Based on the Clinicopathological Data Between Resectable Large-Cell Neuroendocrine Carcinoma and Small-Cell Lung Carcinoma
    Kinoshita, Tomonari
    Yoshida, Junji
    Ishii, Genichiro
    Aokage, Keiju
    Hishida, Tomoyuki
    Nagai, Kanji
    CLINICAL LUNG CANCER, 2013, 14 (05) : 535 - 540
  • [36] Processing-independent quantitation of chromogranin A in plasma from patients with neuroendocrine tumors and small-cell lung carcinomas
    Borglum, Tine
    Rehfeld, Jens F.
    Drivsholm, Lars B.
    Hilsted, Linda
    CLINICAL CHEMISTRY, 2007, 53 (03) : 438 - 446
  • [37] A phase II trial of niraparib plus dostarlimab in relapsed small cell lung cancer and other high-grade neuroendocrine carcinomas
    Gay, Carl M.
    Stewart, C. Allison
    Frumovitz, Michael
    Fujimoto, Junya
    Xi, Yuann
    Wang, Qi
    Wang, Runsheng
    Novegil, Veronica
    Altan, Mehmet
    Cascone, Tina
    Dasari, Arvind
    Elamin, Yasir Y.
    Fossella, Frank V.
    Glisson, Bonnie S.
    Lu, Charles S.
    Negrao, Marcelo V.
    Skoulidis, Ferdinandos
    Vokes, Natalie
    Cardnell, Robert J.
    Wistuba, Ignacio I.
    Wang, Jing
    Heymach, John V.
    Byers, Lauren A.
    CANCER RESEARCH, 2023, 83 (08)
  • [38] Unanticipated heterogeneity in high-grade large-cell neuroendocrine carcinoma pinpoints cell sub-state specific therapeutic targets
    Debnath, O.
    Detjen, K.
    Berger, H.
    Kirchner, P.
    Marinoni, I
    Conrad, T.
    Eils, R.
    Perren, A.
    Wiedenmann, B.
    Ishaque, N.
    JOURNAL OF NEUROENDOCRINOLOGY, 2024, 36 : 24 - 24
  • [39] Gene Expression Profiling of Lung Atypical Carcinoids and Large Cell Neuroendocrine Carcinomas Identifies Three Transcriptomic Subtypes with Specific Genomic Alterations
    Simbolo, Michele
    Barbi, Stefano
    Fassan, Matteo
    Mafficini, Andrea
    Ali, Greta
    Vicentini, Caterina
    Sperandio, Nicola
    Corbo, Vincenzo
    Rusev, Borislav
    Mastracci, Luca
    Grillo, Federica
    Pilotto, Sara
    Pelosi, Giuseppe
    Pelliccioni, Serena
    Lawlor, Rita T.
    Tortora, Giampaolo
    Fontanini, Gabriella
    Volante, Marco
    Scarpa, Aldo
    Bria, Emilio
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (09) : 1651 - 1661
  • [40] Ladademstat effects on neuroendocrine, inflamed and mesenchymal gene expression patterns in small cell lung cancer subtypes
    Sacilotto, N.
    Lufino, M. M. P.
    Pacheco, S.
    Mascaro, C.
    Soliva, R.
    Xaus, J.
    EUROPEAN JOURNAL OF CANCER, 2022, 174 : S67 - S68